Regulatory Evidence

Regulator guidance, submission evidence, inspection readiness, and interpretation.

ClinicalTrials.gov Outcome Measures: Aligning Registry and Protocol Wording

How to write ClinicalTrials.gov outcome measures from the protocol endpoint, which 42 CFR 11.64 update clock applies after an amendment, and what results QC checks.

Oct 618 minBy Ran Chen

An unbranded printed protocol page with blank, unreadable layout blocks, partly overlapped by a plain record card with three empty field rows, next to a capped pen on a wooden desk.

Regulatory Evidence

Patient Input Before Endpoint Selection: Recording What Changed

How clinical trial teams document patient input that alters trial endpoints—creating an attributable record chain across protocol, registry, and TMF.

Sep 2420 minBy Ran Chen

An unbranded dark charcoal study binder with blank index tabs in oxblood, navy, and slate sits beside an archival folder, a compact audio dictation recorder, and a wooden pen on a dark desk.

Regulatory Evidence

TMF Reference Model: Filing the Evidence Behind Endpoint Decisions

How trial teams file endpoint decisions, SAP revisions, eCOA validation, and committee outputs across TMF Reference Model zones for inspection readiness under ICH E6(R3) and EU CTR.

Sep 2325 minBy Ran Chen

Editorial still life of an archival oxblood document drawer with tab dividers, unbranded study binders, sealed parchment document, brass magnifying glass, and blank index card on a wooden desk

Regulatory Evidence

Risk-Based Monitoring: Turning Endpoint Risks Into Review Signals

A structured guide for clinical operations, biostatisticians, and outcome leads to convert protocol endpoint risks into centralized monitoring signals with thresholds and actions under ICH E6(R3) and FDA guidance.

Sep 2220 minBy Ran Chen

Editorial still life of an open blank trial monitoring log, unbranded brass loupe, oxblood ribbon bookmark, and tied study documentation on a dark wooden desk

Regulatory Evidence

How to Construct a COA Endpoint Under Draft PFDD Guidance 4

How clinical trial teams construct endpoints from fit-for-purpose COAs and prespecify meaningful-change interpretation plans under draft PFDD Guidance 4.

Sep 1521 minBy Ran Chen

Editorial still life of an unmarked protocol document, oxblood linen assessment notebook, brass ruler, and fountain pen on warm parchment and navy cloth